Autopsy report · NCT00079326
Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
Cause of deathSlow enrollment
“Slow accrual.”
Life of this trial
- Registered 2 months after it had already started.
- Ran for about 6 years 9 months before it stopped.
- 39 participants enrolled.
- Results were posted on the registry 3 years 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- HER2-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
- Interventions
- trastuzumab; ixabepilone; laboratory biomarker analysis
- Participants
- 39
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.